44 results
8-K
EX-99.2
RCEL
AVITA Medical Inc
10 Jan 24
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
4:05pm
, enhancing the integration of PermeaDerm into our portfolio. This strategic collaboration underscores our commitment to delivering innovative solutions
8-K
EX-10.2
RCEL
AVITA Medical Inc
18 Oct 23
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
9:07am
”), by and among the Borrower, the Lenders party thereto and the Administrative Agent, the Lenders have extended a Commitment to make Loans to the Borrower
8-K
EX-10.1
rvlhqfqjg94747qt 07
18 Oct 23
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
9:07am
8-K
1bwey
18 Oct 23
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
9:07am
424B5
5fqkj 2srz2j41hm
18 Oct 23
Prospectus supplement for primary offering
9:04am
8-K
EX-99.2
hebmd5ei gw
12 May 23
AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance
4:01pm
424B2
j7bhc c9v5
25 Apr 23
Prospectus for primary offering
5:28pm
8-K
EX-99.1
lvuc5g3aq2ate2k
30 Sep 22
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
8:54am
10-KT
gw8tnopoo5z
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
EX-10.29
082oxmcv4cjl6km lx3r
28 Feb 22
Annual report (with FYE transition)
4:11pm
8-K
EX-99.1
9go78sxf
11 Jan 22
Results of Operations and Financial Condition
4:02pm
8-K
EX-10.1
g1jkj
4 Jun 21
Avita Medical, Inc. Appoints Two New Non-executive Members to
6:03am
8-K
EX-10.2
6dh7o6wifgm0gd
4 Jun 21
Avita Medical, Inc. Appoints Two New Non-executive Members to
6:03am
424B5
s0py5u o1jk3p4v7
26 Feb 21
Prospectus supplement for primary offering
12:00am